CMVpp65-A*0201 Peptide Vaccine

A peptide-based cancer vaccine containing a mutated form of the HLA-A*0201-restricted cytomegaloviral epitope CMVpp65(495-503) with potential immunostimulatory and antitumor activities. Upon subcutaneous administration, CMVpp65-A*0201 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against CMV-positive cells, resulting in cell lysis. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity. CMVpp65, a tegument protein of the herpes virus CMV, is the main viral antigen found in peripheral blood mononuclear cells (PBMCs) after viral infection and may activate cell-mediated immunity. (NCI Thesaurus)

YOU MAY ALSO LIKE

CMV N495 Peptide

A peptide derived from cytomegalovirus (CMV) internal matrix protein pp65. CMV pp65 peptide antigen is used in recombinant vaccinia virus as an…

CMV

A virus that may be carried in an inactive state for life by healthy individuals. It is a cause of severe pneumonia…

CMS

A condition that may occur in patients who have had surgery to remove a tumor in certain parts of the brain, including…

CMML

A slowly progressing type of myelodysplastic/myeloproliferative disease in which too many myelomonocytes (a type of white blood cell) are in the bone…

CML

A slowly progressing disease in which too many white blood cells (not lymphocytes) are made in the bone marrow. Also called chronic…

CMKLR1 wt Allele

Human CMKLR1 wild-type allele is located in the vicinity of 12q24.1 and is approximately 48 kb in length. This allele, which encodes…